Akari Therapeutics, Plc (AKTX) 10-Year Financial Performance & Capital Metrics

AKTX •

HealthcareBiotechnologyImmunology and Inflammation Therapies

AboutAkari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.Show more

Revenue $0
EBITDA -$22M -28.7%
Net Income -$20M -97.8%
EPS (Diluted) -1660.00 -730.0%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -179.92% +86.0%
ROIC -172.54%
Debt/Equity 0.15
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Trading at only 0.0x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Weak momentum: RS Rating 7 (bottom 7%)
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM21.94%

EPS CAGR

10Y-

5Y-

3Y-

TTM-4230.52%

ROCE

10Y Avg-410.67%

5Y Avg-681.17%

3Y Avg-974.25%

Latest-142.28%

Peer Comparison

Immunology and Inflammation Therapies

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TGTXTG Therapeutics, Inc.	4.75B	30.09	200.60	40.8%	13.31%	21.87%		1.14
APLSApellis Pharmaceuticals, Inc.	2.65B	20.96	116.44	-11.77%	3.25%	7.48%	1.71%	0.30
ARGXargenx SE	47.46B	766.92	60.01	78.6%	23.34%	15.14%		0.01
KNSAKiniksa Pharmaceuticals, Ltd.	3.39B	44.49	59.32	60.09%	17.52%	20.92%	0.75%	0.02
AUPHAurinia Pharmaceuticals Inc.	1.88B	14.17	6.85	20.38%	101.47%	49.4%	7.22%	0.13
GLPGGalapagos N.V.	2.22B	33.66	5.88	303.48%	28.85%	9.92%		0.00
AKTXAkari Therapeutics, Plc	12.56B	0.24	-0.00			-69.35%		0.15
RAPTRAPT Therapeutics, Inc.	7.65B	57.98	-2.27			-69.51%		0.02

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	10.16K	39.77K	42.4K	35.85K	19.2K	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-10.16K	-39.77K	-42.4K	-35.85K	-19.2K	0	0	0	0	0
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-291.5%	-6.61%	15.45%	46.43%	100%	-	-	-	-
Operating Expenses+	11.3M	27.25M	34.96M	23.8M	24.85M	17.98M	17.21M	23.09M	16.81M	21.64M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	5.5M	9.94M	11.67M	10.9M	8.2M	9.16M	8.08M	13.53M	11.36M	9.66M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	5.8M	17.31M	23.29M	15.59M	16.65M	12.19M	9.13M	9.56M	8.02M	6.98M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	-44.22K	-43.97K	-13.39K	-2.68M	0	-3.37M	0	0	-2.57M	5M
Operating Income+	-30.58M	-27.25M	-34.96M	-19.99M	-24.87M	-17.98M	-17.21M	-23.09M	-16.81M	-21.64M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-200.53%	10.91%	-28.31%	42.81%	-24.4%	27.7%	4.26%	-34.12%	27.21%	-28.78%
EBITDA+	-30.57M	-27.21M	-34.92M	-19.96M	-24.85M	-17.97M	-17.21M	-23.08M	-16.8M	-21.63M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-200.66%	11.01%	-28.34%	42.85%	-24.53%	27.68%	4.24%	-34.13%	27.21%	-28.73%
D&A (Non-Cash Add-back)	10.16K	39.77K	42.4K	35.85K	19.2K	8.91K	4.13K	4K	4K	14K
EBIT	-19.29M	-27.25M	-35.4M	-16.47M	-24.75M	-17.98M	-17.21M	-23.09M	-16.81M	-19.55M
Net Interest Income+	-3.03M	-9.01M	0	222.26K	5K	13K	10.6K	45.94K	82K	252K
Interest Income	20.7K	143.19K	175.39K	222.26K	5K	13K	10.6K	45.94K	82K	8K
Interest Expense	3.05M	9.15M	0	0	0	0	0	0	0	-244K
Other Income/Expense	-14.72M	9.11M	2.38M	-507.93K	116.92K	899.36K	-210.1K	5.34M	6.8M	1.85M
Pretax Income+	-45.32M	-18.14M	-32.57M	-23.5M	-24.75M	-17.08M	-17.42M	-17.75M	-10.01M	-19.79M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	0	-43.97K	-4.65M	-3.55M	-7.91M	0	0	0	0	0
Effective Tax Rate %	100%	100%	85.72%	84.89%	68.06%	100%	100%	100%	100%	100%
Net Income+	-45.32M	-18.14M	-27.92M	-19.95M	-16.85M	-17.08M	-17.42M	-17.75M	-10.01M	-19.79M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-369.71%	59.97%	-53.93%	28.56%	15.56%	-1.4%	-2.01%	-1.86%	43.61%	-97.75%
Net Income (Continuing)	-45.32M	-18.06M	-35.4M	-16.47M	-16.85M	-17.08M	-17.42M	-17.75M	-10.01M	-19.79M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-10640.00	-3080.00	-4480.00	-2520.00	-2380.00	-1120.00	-820.00	-220.00	-200.00	-1660.00
EPS Growth %	-119.83%	71.05%	-45.45%	43.75%	5.56%	52.94%	26.79%	73.17%	9.09%	-730%
EPS (Basic)	-10640.00	-3080.00	-4480.00	-2520.00	-2380.00	-1560.00	-820.00	-220.00	-200.00	-1660.00
Diluted Shares Outstanding	426	588	623	790	915	1.58K	2.15K	3.12K	4.89K	11.94K
Basic Shares Outstanding	426	588	623	790	915	1.12K	2.15K	3.12K	4.89K	11.94K
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	69.66M	45.63M	28.81M	16.4M	10.27M	14.58M	11.63M	13.81M	4.34M	2.95M
Cash & Short-Term Investments	68.92M	44.12M	28.11M	5.97M	5.73M	14.06M	9.36M	13.25M	3.85M	2.6M
Cash Only	68.92M	34.1M	28.11M	5.97M	5.73M	14.06M	9.36M	13.25M	3.85M	2.6M
Short-Term Investments	0	10.02M	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	0	0	0	0	0	0	0	201K
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	-1.87K	0	0	-2.01M	-1.03M	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	706.41K	585K	0	229.2K	90.3K	100K	197K	60K
Total Non-Current Assets+	235.07K	239.9K	237.26K	53K	35K	27.15K	22.93K	17K	14K	47.61M
Property, Plant & Equipment	40.51K	58.36K	55.9K	20K	5K	0	0	0	0	0
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	8.43M
Intangible Assets	52.48K	39.37K	39.12K	33K	30K	27.15K	22.93K	17K	14K	39.18M
Long-Term Investments	142.08K	143.67K	142.24K	521.83K	0	0	0	0	0	0
Other Non-Current Assets	142.08K	142.17K	142.24K	585K	0	0	0	0	0	0
Total Assets+	69.89M	45.87M	29.05M	16.45M	10.31M	14.6M	11.65M	13.83M	4.36M	50.56M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	978.6%	-34.37%	-36.67%	-43.37%	-37.35%	41.7%	-20.25%	18.75%	-68.52%	1061.01%
Total Current Liabilities+	21.12M	11.71M	9.02M	3.08M	5.46M	5.22M	6.09M	12.04M	4.58M	19.91M
Accounts Payable	4.32M	2.21M	1.97M	1.59M	1.23M	3.38M	1.79M	947K	1.67M	12.41M
Days Payables Outstanding	155.23K	20.32K	16.97K	16.15K	23.35K	-	-	-	-	-
Short-Term Debt	0	0	0	0	0	0	0	0	0	3.26M
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	16.4M	7.66M	7.78M	1.84M	1.01M	0	1.12M	7.95M	2.73M	1.58M
Current Ratio	3.30x	3.90x	3.19x	5.33x	1.88x	2.79x	1.91x	1.15x	0.95x	0.15x
Quick Ratio	3.30x	3.90x	3.19x	5.98x	2.07x	2.79x	1.91x	1.15x	0.95x	0.15x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	49.07K	56.36K	48K	0	1.01M	0	0	0	0	8.42M
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	8.04M
Other Non-Current Liabilities	49.07K	56.36K	48K	0	0	0	0	0	0	383K
Total Liabilities	21.17M	11.77M	9.07M	3.08M	6.47M	5.22M	6.09M	12.04M	4.58M	28.33M
Total Debt+	0	0	0	0	0	0	0	0	0	3.26M
Net Debt	-68.92M	-34.1M	-28.11M	-5.97M	-5.73M	-14.06M	-9.36M	-13.25M	-3.85M	661K
Debt / Equity	-	-	-	-	-	-	-	-	-	0.15x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-10.01x	-2.98x	-	-	-	-	-	-	-	-
Total Equity+	48.72M	34.1M	19.98M	13.38M	3.84M	9.38M	5.55M	1.79M	-229K	22.23M
Equity Growth %	903.91%	-30%	-41.41%	-33.05%	-71.32%	144.64%	-40.81%	-67.76%	-112.79%	9806.99%
Book Value per Share	114365.08	57997.53	32068.97	16931.65	4192.35	5943.20	2588.34	573.85	-46.79	1861.10
Total Shareholders' Equity	48.72M	34.1M	19.98M	13.38M	3.84M	9.38M	5.55M	1.79M	-229K	22.23M
Common Stock	18.34M	18.34M	22.93M	23.65M	31.99M	384.73K	475.97K	745K	1.32M	5.32M
Retained Earnings	-56.8M	-74.94M	-107.51M	-116.47M	-138.24M	-182.28M	-199.71M	-217.45M	-227.46M	-247.25M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	156.48K	-280.1K	-236.25K	-12.25M	-12.24M	-648.07K	51.65M	51.42M	51.15M	-738K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-4.97M	-24.62M	-31.6M	-22.54M	-12.92M	-16.95M	-18.85M	-21.5M	-16.43M	-12.55M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	47.52%	-395.9%	-28.32%	28.68%	42.68%	-31.21%	-11.19%	-14.1%	23.59%	23.61%
Net Income	-45.32M	-18.14M	-35.4M	-23.5M	-16.85M	-17.08M	-17.42M	-17.75M	-10.01M	-19.79M
Depreciation & Amortization	10.16K	39.94K	42.4K	39K	19.2K	8.91K	4.13K	4K	4K	14K
Stock-Based Compensation	1.79M	3.93M	2.73M	1.65M	1.05M	325.52K	314.65K	735K	1.15M	2.25M
Deferred Taxes	-11.41M	-3	-2.49M	0	0	0	0	0	0	0
Other Non-Cash Items	45.29M	-9.01M	2.7M	-105K	-229.31K	-147.59K	242.5K	-5.32M	-6.71M	-1.56M
Working Capital Changes	4.67M	-1.45M	811.27K	-619K	3.09M	-55.63K	-1.98M	822K	-866K	6.54M
Change in Receivables	0	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	3.76B	-671.78K	12.22K	-3.69M	0	0	-241.31K	0	0	0
Cash from Investing+	1.39M	-10.07M	9.99M	0	0	0	0	0	0	382K
Capital Expenditures	-10.56K	-54.75K	-36.88K	0	0	0	0	0	0	0
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	1.41M	0	0	0	0	0	0	0	0	382K
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-8.22K	10.08K	10.02K	0	0	0	0	0	0	0
Cash from Financing+	69.04M	0	15.67M	306K	12.65M	25.07M	14.29M	25.29M	7.02M	10.99M
Debt Issued (Net)	0	0	0	0	0	0	0	0	0	-855K
Equity Issued (Net)	1000K	0	1000K	500K	1000K	1000K	1000K	1000K	1000K	1000K
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	0	0	0	0	0	0	0	0	0	0
Other Financing	-5.96M	0	0	-194K	0	27.5K	0	94K	4K	28K
Net Change in Cash	65.59M	-34.82M	-5.99M	-22.28M	-236.28K	8.32M	-4.69M	3.89M	-9.4M	-1.19M
Free Cash Flow+	-4.98M	-24.68M	-31.64M	-22.54M	-12.92M	-16.95M	-18.85M	-21.5M	-16.43M	-12.55M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	47.72%	-395.95%	-28.19%	28.76%	42.68%	-31.21%	-11.19%	-14.1%	23.59%	23.61%
FCF per Share	-11681.09	-41971.57	-50779.44	-28526.58	-14118.37	-10734.90	-8782.17	-6890.10	-3357.58	-1050.90
FCF Conversion (FCF/Net Income)	0.11x	1.36x	1.13x	1.13x	0.77x	0.99x	1.08x	1.21x	1.64x	0.63x
Interest Paid	0	0	0	0	0	0	0	0	0	143K
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-169.18%	-43.81%	-103.27%	-119.62%	-195.75%	-258.41%	-233.27%	-483.23%	-1281.43%	-179.92%
Return on Invested Capital (ROIC)	-	-546680.54%	-	-202.4%	-676.81%	-	-	-	-	-172.54%
Debt / Equity	-	-	-	-	-	-	-	-	-	0.15x
Interest Coverage	-10.01x	-2.98x	-	-	-	-	-	-	-	-
FCF Conversion	0.11x	1.36x	1.13x	1.13x	0.77x	0.99x	1.08x	1.21x	1.64x	0.63x

US Stock Screener

...

Akari Therapeutics, Plc (AKTX) 10-Year Financial Performance & Capital Metrics

AKTX •

HealthcareBiotechnologyImmunology and Inflammation Therapies

Revenue $0
EBITDA -$22M -28.7%
Net Income -$20M -97.8%
EPS (Diluted) -1660.00 -730.0%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -179.92% +86.0%
ROIC -172.54%
Debt/Equity 0.15
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Trading at only 0.0x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Weak momentum: RS Rating 7 (bottom 7%)
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM21.94%

EPS CAGR

10Y-

5Y-

3Y-

TTM-4230.52%

ROCE

10Y Avg-410.67%

5Y Avg-681.17%

3Y Avg-974.25%

Latest-142.28%

Peer Comparison

Immunology and Inflammation Therapies

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TGTXTG Therapeutics, Inc.	4.75B	30.09	200.60	40.8%	13.31%	21.87%		1.14
APLSApellis Pharmaceuticals, Inc.	2.65B	20.96	116.44	-11.77%	3.25%	7.48%	1.71%	0.30
ARGXargenx SE	47.46B	766.92	60.01	78.6%	23.34%	15.14%		0.01
KNSAKiniksa Pharmaceuticals, Ltd.	3.39B	44.49	59.32	60.09%	17.52%	20.92%	0.75%	0.02
AUPHAurinia Pharmaceuticals Inc.	1.88B	14.17	6.85	20.38%	101.47%	49.4%	7.22%	0.13
GLPGGalapagos N.V.	2.22B	33.66	5.88	303.48%	28.85%	9.92%		0.00
AKTXAkari Therapeutics, Plc	12.56B	0.24	-0.00			-69.35%		0.15
RAPTRAPT Therapeutics, Inc.	7.65B	57.98	-2.27			-69.51%		0.02

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	10.16K	39.77K	42.4K	35.85K	19.2K	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-10.16K	-39.77K	-42.4K	-35.85K	-19.2K	0	0	0	0	0
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-291.5%	-6.61%	15.45%	46.43%	100%	-	-	-	-
Operating Expenses+	11.3M	27.25M	34.96M	23.8M	24.85M	17.98M	17.21M	23.09M	16.81M	21.64M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	5.5M	9.94M	11.67M	10.9M	8.2M	9.16M	8.08M	13.53M	11.36M	9.66M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	5.8M	17.31M	23.29M	15.59M	16.65M	12.19M	9.13M	9.56M	8.02M	6.98M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	-44.22K	-43.97K	-13.39K	-2.68M	0	-3.37M	0	0	-2.57M	5M
Operating Income+	-30.58M	-27.25M	-34.96M	-19.99M	-24.87M	-17.98M	-17.21M	-23.09M	-16.81M	-21.64M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-200.53%	10.91%	-28.31%	42.81%	-24.4%	27.7%	4.26%	-34.12%	27.21%	-28.78%
EBITDA+	-30.57M	-27.21M	-34.92M	-19.96M	-24.85M	-17.97M	-17.21M	-23.08M	-16.8M	-21.63M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-200.66%	11.01%	-28.34%	42.85%	-24.53%	27.68%	4.24%	-34.13%	27.21%	-28.73%
D&A (Non-Cash Add-back)	10.16K	39.77K	42.4K	35.85K	19.2K	8.91K	4.13K	4K	4K	14K
EBIT	-19.29M	-27.25M	-35.4M	-16.47M	-24.75M	-17.98M	-17.21M	-23.09M	-16.81M	-19.55M
Net Interest Income+	-3.03M	-9.01M	0	222.26K	5K	13K	10.6K	45.94K	82K	252K
Interest Income	20.7K	143.19K	175.39K	222.26K	5K	13K	10.6K	45.94K	82K	8K
Interest Expense	3.05M	9.15M	0	0	0	0	0	0	0	-244K
Other Income/Expense	-14.72M	9.11M	2.38M	-507.93K	116.92K	899.36K	-210.1K	5.34M	6.8M	1.85M
Pretax Income+	-45.32M	-18.14M	-32.57M	-23.5M	-24.75M	-17.08M	-17.42M	-17.75M	-10.01M	-19.79M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	0	-43.97K	-4.65M	-3.55M	-7.91M	0	0	0	0	0
Effective Tax Rate %	100%	100%	85.72%	84.89%	68.06%	100%	100%	100%	100%	100%
Net Income+	-45.32M	-18.14M	-27.92M	-19.95M	-16.85M	-17.08M	-17.42M	-17.75M	-10.01M	-19.79M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-369.71%	59.97%	-53.93%	28.56%	15.56%	-1.4%	-2.01%	-1.86%	43.61%	-97.75%
Net Income (Continuing)	-45.32M	-18.06M	-35.4M	-16.47M	-16.85M	-17.08M	-17.42M	-17.75M	-10.01M	-19.79M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-10640.00	-3080.00	-4480.00	-2520.00	-2380.00	-1120.00	-820.00	-220.00	-200.00	-1660.00
EPS Growth %	-119.83%	71.05%	-45.45%	43.75%	5.56%	52.94%	26.79%	73.17%	9.09%	-730%
EPS (Basic)	-10640.00	-3080.00	-4480.00	-2520.00	-2380.00	-1560.00	-820.00	-220.00	-200.00	-1660.00
Diluted Shares Outstanding	426	588	623	790	915	1.58K	2.15K	3.12K	4.89K	11.94K
Basic Shares Outstanding	426	588	623	790	915	1.12K	2.15K	3.12K	4.89K	11.94K
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	69.66M	45.63M	28.81M	16.4M	10.27M	14.58M	11.63M	13.81M	4.34M	2.95M
Cash & Short-Term Investments	68.92M	44.12M	28.11M	5.97M	5.73M	14.06M	9.36M	13.25M	3.85M	2.6M
Cash Only	68.92M	34.1M	28.11M	5.97M	5.73M	14.06M	9.36M	13.25M	3.85M	2.6M
Short-Term Investments	0	10.02M	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	0	0	0	0	0	0	0	201K
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	-1.87K	0	0	-2.01M	-1.03M	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	706.41K	585K	0	229.2K	90.3K	100K	197K	60K
Total Non-Current Assets+	235.07K	239.9K	237.26K	53K	35K	27.15K	22.93K	17K	14K	47.61M
Property, Plant & Equipment	40.51K	58.36K	55.9K	20K	5K	0	0	0	0	0
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	8.43M
Intangible Assets	52.48K	39.37K	39.12K	33K	30K	27.15K	22.93K	17K	14K	39.18M
Long-Term Investments	142.08K	143.67K	142.24K	521.83K	0	0	0	0	0	0
Other Non-Current Assets	142.08K	142.17K	142.24K	585K	0	0	0	0	0	0
Total Assets+	69.89M	45.87M	29.05M	16.45M	10.31M	14.6M	11.65M	13.83M	4.36M	50.56M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	978.6%	-34.37%	-36.67%	-43.37%	-37.35%	41.7%	-20.25%	18.75%	-68.52%	1061.01%
Total Current Liabilities+	21.12M	11.71M	9.02M	3.08M	5.46M	5.22M	6.09M	12.04M	4.58M	19.91M
Accounts Payable	4.32M	2.21M	1.97M	1.59M	1.23M	3.38M	1.79M	947K	1.67M	12.41M
Days Payables Outstanding	155.23K	20.32K	16.97K	16.15K	23.35K	-	-	-	-	-
Short-Term Debt	0	0	0	0	0	0	0	0	0	3.26M
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	16.4M	7.66M	7.78M	1.84M	1.01M	0	1.12M	7.95M	2.73M	1.58M
Current Ratio	3.30x	3.90x	3.19x	5.33x	1.88x	2.79x	1.91x	1.15x	0.95x	0.15x
Quick Ratio	3.30x	3.90x	3.19x	5.98x	2.07x	2.79x	1.91x	1.15x	0.95x	0.15x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	49.07K	56.36K	48K	0	1.01M	0	0	0	0	8.42M
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	8.04M
Other Non-Current Liabilities	49.07K	56.36K	48K	0	0	0	0	0	0	383K
Total Liabilities	21.17M	11.77M	9.07M	3.08M	6.47M	5.22M	6.09M	12.04M	4.58M	28.33M
Total Debt+	0	0	0	0	0	0	0	0	0	3.26M
Net Debt	-68.92M	-34.1M	-28.11M	-5.97M	-5.73M	-14.06M	-9.36M	-13.25M	-3.85M	661K
Debt / Equity	-	-	-	-	-	-	-	-	-	0.15x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-10.01x	-2.98x	-	-	-	-	-	-	-	-
Total Equity+	48.72M	34.1M	19.98M	13.38M	3.84M	9.38M	5.55M	1.79M	-229K	22.23M
Equity Growth %	903.91%	-30%	-41.41%	-33.05%	-71.32%	144.64%	-40.81%	-67.76%	-112.79%	9806.99%
Book Value per Share	114365.08	57997.53	32068.97	16931.65	4192.35	5943.20	2588.34	573.85	-46.79	1861.10
Total Shareholders' Equity	48.72M	34.1M	19.98M	13.38M	3.84M	9.38M	5.55M	1.79M	-229K	22.23M
Common Stock	18.34M	18.34M	22.93M	23.65M	31.99M	384.73K	475.97K	745K	1.32M	5.32M
Retained Earnings	-56.8M	-74.94M	-107.51M	-116.47M	-138.24M	-182.28M	-199.71M	-217.45M	-227.46M	-247.25M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	156.48K	-280.1K	-236.25K	-12.25M	-12.24M	-648.07K	51.65M	51.42M	51.15M	-738K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-4.97M	-24.62M	-31.6M	-22.54M	-12.92M	-16.95M	-18.85M	-21.5M	-16.43M	-12.55M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	47.52%	-395.9%	-28.32%	28.68%	42.68%	-31.21%	-11.19%	-14.1%	23.59%	23.61%
Net Income	-45.32M	-18.14M	-35.4M	-23.5M	-16.85M	-17.08M	-17.42M	-17.75M	-10.01M	-19.79M
Depreciation & Amortization	10.16K	39.94K	42.4K	39K	19.2K	8.91K	4.13K	4K	4K	14K
Stock-Based Compensation	1.79M	3.93M	2.73M	1.65M	1.05M	325.52K	314.65K	735K	1.15M	2.25M
Deferred Taxes	-11.41M	-3	-2.49M	0	0	0	0	0	0	0
Other Non-Cash Items	45.29M	-9.01M	2.7M	-105K	-229.31K	-147.59K	242.5K	-5.32M	-6.71M	-1.56M
Working Capital Changes	4.67M	-1.45M	811.27K	-619K	3.09M	-55.63K	-1.98M	822K	-866K	6.54M
Change in Receivables	0	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	3.76B	-671.78K	12.22K	-3.69M	0	0	-241.31K	0	0	0
Cash from Investing+	1.39M	-10.07M	9.99M	0	0	0	0	0	0	382K
Capital Expenditures	-10.56K	-54.75K	-36.88K	0	0	0	0	0	0	0
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	1.41M	0	0	0	0	0	0	0	0	382K
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-8.22K	10.08K	10.02K	0	0	0	0	0	0	0
Cash from Financing+	69.04M	0	15.67M	306K	12.65M	25.07M	14.29M	25.29M	7.02M	10.99M
Debt Issued (Net)	0	0	0	0	0	0	0	0	0	-855K
Equity Issued (Net)	1000K	0	1000K	500K	1000K	1000K	1000K	1000K	1000K	1000K
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	0	0	0	0	0	0	0	0	0	0
Other Financing	-5.96M	0	0	-194K	0	27.5K	0	94K	4K	28K
Net Change in Cash	65.59M	-34.82M	-5.99M	-22.28M	-236.28K	8.32M	-4.69M	3.89M	-9.4M	-1.19M
Free Cash Flow+	-4.98M	-24.68M	-31.64M	-22.54M	-12.92M	-16.95M	-18.85M	-21.5M	-16.43M	-12.55M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	47.72%	-395.95%	-28.19%	28.76%	42.68%	-31.21%	-11.19%	-14.1%	23.59%	23.61%
FCF per Share	-11681.09	-41971.57	-50779.44	-28526.58	-14118.37	-10734.90	-8782.17	-6890.10	-3357.58	-1050.90
FCF Conversion (FCF/Net Income)	0.11x	1.36x	1.13x	1.13x	0.77x	0.99x	1.08x	1.21x	1.64x	0.63x
Interest Paid	0	0	0	0	0	0	0	0	0	143K
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-169.18%	-43.81%	-103.27%	-119.62%	-195.75%	-258.41%	-233.27%	-483.23%	-1281.43%	-179.92%
Return on Invested Capital (ROIC)	-	-546680.54%	-	-202.4%	-676.81%	-	-	-	-	-172.54%
Debt / Equity	-	-	-	-	-	-	-	-	-	0.15x
Interest Coverage	-10.01x	-2.98x	-	-	-	-	-	-	-	-
FCF Conversion	0.11x	1.36x	1.13x	1.13x	0.77x	0.99x	1.08x	1.21x	1.64x	0.63x

Akari Therapeutics, Plc (AKTX) 10-Year Financial Performance & Capital Metrics

Key Insights

✓Strengths

✗Weaknesses

Price & Volume

Growth Metrics

Revenue CAGR

Profit (Net Income) CAGR

EPS CAGR

ROCE

Peer Comparison

Compare AKTX vs Peers

vs ARGX

vs CANF

Compare Top 5

Profit & Loss

Balance Sheet

Cash Flow

Key Ratios

Deep Dive Analysis

Valuation Overview

Total Return Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Akari Therapeutics, Plc (AKTX) 10-Year Financial Performance & Capital Metrics

Key Insights

✓Strengths

✗Weaknesses

Price & Volume

Growth Metrics

Revenue CAGR

Profit (Net Income) CAGR

EPS CAGR

ROCE

Peer Comparison

Compare AKTX vs Peers

vs ARGX

vs CANF

Compare Top 5

Profit & Loss

Balance Sheet

Cash Flow

Key Ratios

Deep Dive Analysis

Valuation Overview

Total Return Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios